Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare ...
Hosted on MSN
Down 37% in 4 weeks, here's why Aquestive Therapeutics (AQST) looks ripe for a turnaround
A downtrend has been apparent in Aquestive Therapeutics (AQST) lately with too much selling pressure. The stock has declined 37% over the past four weeks. However, given the fact that it is now in ...
We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Aquestive Therapeutics, Inc. (NASDAQ:AQST) stands against ...
FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studies FDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance ...
Aquestive Therapeutics (AQST) reported $11.87 million in revenue for the quarter ended December 2024, representing a year-over-year decline of 10.2%. EPS of -$0.19 for the same period compares to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results